Non-Bismuth Quadruple Therapy, Sequential Therapy or High-Dose Esomeprazole and Amoxicillin Dual Therapy for First-Line Helicobacter pylori Eradication: A Prospective Randomized Study
Open Access
- 2 December 2020
- journal article
- research article
- Published by Springer Science and Business Media LLC in Cureus
- Vol. 12 (12)
- https://doi.org/10.7759/cureus.11837
Abstract
Aim: The study aims were to evaluate and compare the effectiveness and safety of non-bismuth quadruple therapy with sequential therapy and dual therapy with high dose esomeprazole and amoxicillin as an empirical first-line approach to eradicate Helicobacter pylori infection. Patients and methods: Prospective randomized trial included 393 patients infected with H. pylori naïve to eradication therapy, randomized to receive a 10-day non-bismuth quadruple or concomitant (CT) therapy, 10-day sequential therapy (SQ), or 14-day high-dose esomeprazole and amoxicillin (BT). Treatment outcome was assessed by C13-urea breath test at least six weeks after therapy. Adverse events and compliance were assessed with questionnaires and residual medication count. Results: The baseline demographic clinical and endoscopic characteristics were similar among the three groups. The intention to treat (ITT) analysis was performed in 130, 132, and 131 patients in the BT, SQ, and CT groups, respectively. The eradication rates in ITT were 64.6%, 83.1%, and 92.3%, respectively, in the BT, SQ and CT groups (p = 0.0001). The eradication rates per protocol were 67.7%, 88.5%, and 95.3% (p = 0.0001), respectively, in the BT, SQ, and CT groups. The CT and SQ groups were higher than the BT group (p = 0,0001) but no significant results were seen in the eradication rate between CT and SQ, both in PP analysis and in ITT analysis (p = 0.09). The prevalence of the side effects following the non-bismuth quadruple therapy was 38.2%, significantly higher (p = 0.001) than the BT group (13.80%) and SQ group (22%). There were no significant differences in compliance among the three therapies (p = 0.16). Conclusion: This study found that non-bismuth quadruple therapy yielded a higher H. pylori eradication rate over sequential regimen as a first-line treatment in Morocco, with no statistical difference between the two protocols studied, while the eradication rate of dual high-dose of esomeprazole and amoxicillin did not exceed 60%. All three therapy schemes showed excellent compliance. However, the prevalence of side events was more important and significantly higher with non-bismuth quadruple therapy.This publication has 27 references indexed in Scilit:
- Sequential therapy versus standard triple-drug therapy for Helicobacter pylori eradication: Result of the HPFEZ randomised studyClinics and Research in Hepatology and Gastroenterology, 2013
- Management ofHelicobacter pyloriinfection—the Maastricht IV/ Florence Consensus ReportGut, 2012
- World Gastroenterology Organisation Global GuidelineJournal of Clinical Gastroenterology, 2011
- Sequential and Concomitant Therapy With Four Drugs Is Equally Effective for Eradication of H pylori InfectionClinical Gastroenterology and Hepatology, 2010
- Helicobacter pyloriDetection and Antimicrobial Susceptibility TestingClinical Microbiology Reviews, 2007
- Ingestion of Acidic Foods Mimics Gastroesophageal Reflux During pH MonitoringDigestive Diseases and Sciences, 2005
- Pharmacology of the gastric mucosa: A rational approach to Helicobacter polytherapyGastroenterology, 1996
- Double-blind trial of omeprazole and amoxicillin to cure Helicobacter pylori infection in patients with duodenal ulcersGastroenterology, 1995
- Effect of pH variation on the susceptibility ofHelicobacter pylori to three macrolide antimicrobial agents and temafloxacinEuropean Journal of Clinical Microbiology & Infectious Diseases, 1993
- Effect of varying pH on the susceptibility ofCampylobacter pylori to antimicrobial agentsEuropean Journal of Clinical Microbiology & Infectious Diseases, 1989